Results from the second Phase 3 trial evaluating semaglutide 7.2 mg in adults with T2D and obesity (STEP UP T2D) are anticipated in the coming months, according to the company
A case series published in Medicine ( Mawardi et al
If side effects worsen after 23 weeks, contact your providers immediatelydose adjustments to either medication, or a switch to a different compound, may be necessary
For patients reporting urinary side effects during care, the prescribing clinician can review symptoms, screen for red flags, and recommend further evaluation when needed
doi: 10.1038/d41586-023-03143-x
This inflammatory state, termed inflammaging, is one of the most consistent features of biological aging and correlates with nearly every major age-related disease [8]